GlaxoSmithKline LLC Withdraws FDA Approval for BEXXAR Treatment for Certain Non-Hodgkin's Lymphoma Patients

Summary

GlaxoSmithKline LLC has voluntarily withdrawn FDA approval for the use of BEXXAR (tositumomab and iodine I 131 tositumomab) Injection to treat patients with relapsed or refractory, low-grade, follicular, or transformed CD20-positive non-Hodgkin's lymphoma who have not received prior rituximab therapy.